Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular DystrophyAnne M. Connolly, Ewa Carrier, Cuixia Tian et al.|Journal of Neuromuscular Diseases|2023Cited by 24
A phase I, first-in-human, open-label, dose escalation and expansion study of PT886 in adult patients with advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas.Michael J. Overman, Harold M. Wright, Ramzi Melhem et al.|Journal of Clinical Oncology|2023Cited by 18
Abstract 4260: PT886, an anti-claudin18.2/anti-CD47 bispecific antibody constructed with the PACbody and SPECpair technology platforms, exhibits robust anti-tumor activity in a pancreatic cancer xenograft modelJack Li, Hui Zou, Haiqun Jia et al.|Cancer Research|2022Cited by 7
Abstract 4259: PT199, a next generation anti-CD73 mAb that inhibits both membrane-bound and soluble CD73 activity to completion without “hook effect”Haiqun Jia, Hui Zou, Jessica Perer et al.|Cancer Research|2022Cited by 4